M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:M12 - DE000A0STSQ8 - Common Stock
15.9 EUR
-0.52 (-3.17%)
We assign a fundamental rating of 7 out of 10 to M12. M12 was compared to 27 industry peers in the Health Care Providers & Services industry. M12 gets an excellent profitability rating and is at the same time showing great financial health properties. M12 is not valued too expensively and it also shows a decent growth rate. This makes M12 very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year M12 was profitable.
M12 had a positive operating cash flow in the past year.
In the past 5 years M12 has always been profitable.
M12 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
M12's Return On Assets of 8.73% is amongst the best of the industry. M12 outperforms 96.30% of its industry peers.
The Return On Equity of M12 (15.03%) is better than 74.07% of its industry peers.
Looking at the Return On Invested Capital, with a value of 13.44%, M12 belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
M12 had an Average Return On Invested Capital over the past 3 years of 7.72%. This is in line with the industry average of 6.90%.
The 3 year average ROIC (7.72%) for M12 is below the current ROIC(13.44%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
M12's Profit Margin of 5.00% is amongst the best of the industry. M12 outperforms 81.48% of its industry peers.
In the last couple of years the Profit Margin of M12 has declined.
With a decent Operating Margin value of 8.52%, M12 is doing good in the industry, outperforming 74.07% of the companies in the same industry.
In the last couple of years the Operating Margin of M12 has declined.
The Gross Margin of M12 (19.29%) is comparable to the rest of the industry.
M12's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), M12 is creating value.
M12 has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, M12 has more shares outstanding
The debt/assets ratio for M12 is higher compared to a year ago.
2.2 Solvency
M12 has an Altman-Z score of 5.42. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
M12's Altman-Z score of 5.42 is amongst the best of the industry. M12 outperforms 100.00% of its industry peers.
M12 has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
M12 has a Debt to FCF ratio of 0.70. This is amongst the best in the industry. M12 outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that M12 is not too dependend on debt financing.
The Debt to Equity ratio of M12 (0.05) is better than 96.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.42 |
ROIC/WACC1.88
WACC7.16%
2.3 Liquidity
A Current Ratio of 2.06 indicates that M12 has no problem at all paying its short term obligations.
With an excellent Current ratio value of 2.06, M12 belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
M12 has a Quick Ratio of 1.35. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.35, M12 is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.36% over the past year.
M12 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.97% yearly.
M12 shows a small growth in Revenue. In the last year, the Revenue has grown by 6.52%.
Measured over the past years, M12 shows a very strong growth in Revenue. The Revenue has been growing by 34.44% on average per year.
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
The Earnings Per Share is expected to grow by 19.18% on average over the next years. This is quite good.
The Revenue is expected to grow by 8.24% on average over the next years. This is quite good.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.91, the valuation of M12 can be described as correct.
The rest of the industry has a similar Price/Earnings ratio as M12.
When comparing the Price/Earnings ratio of M12 to the average of the S&P500 Index (25.47), we can say M12 is valued slightly cheaper.
M12 is valuated correctly with a Price/Forward Earnings ratio of 13.70.
Based on the Price/Forward Earnings ratio, M12 is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.42, M12 is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.91 | ||
| Fwd PE | 13.7 |
4.2 Price Multiples
M12's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. M12 is cheaper than 74.07% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of M12 indicates a somewhat cheap valuation: M12 is cheaper than 70.37% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.7 | ||
| EV/EBITDA | 7.7 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates M12 does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of M12 may justify a higher PE ratio.
A more expensive valuation may be justified as M12's earnings are expected to grow with 19.18% in the coming years.
PEG (NY)3.26
PEG (5Y)2.12
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.05%, M12 has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.09, M12 pays a better dividend. On top of this M12 pays more dividend than 92.59% of the companies listed in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (11/21/2025, 7:00:00 PM)
15.9
-0.52 (-3.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.8%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap312.28M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target27.03 (70%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.91 | ||
| Fwd PE | 13.7 | ||
| P/S | 0.88 | ||
| P/FCF | 11.7 | ||
| P/OCF | 11.55 | ||
| P/B | 2.65 | ||
| P/tB | 11.37 | ||
| EV/EBITDA | 7.7 |
EPS(TTM)0.94
EY5.91%
EPS(NY)1.16
Fwd EY7.3%
FCF(TTM)1.36
FCFY8.55%
OCF(TTM)1.38
OCFY8.66%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)3.26
PEG (5Y)2.12
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.42 |
F-Score9
WACC7.16%
ROIC/WACC1.88
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year31.44%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 7 / 10 to M12.DE.
Can you provide the valuation status for M1 KLINIKEN AG?
ChartMill assigns a valuation rating of 5 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of M1 KLINIKEN AG (M12.DE) stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 16.91 and the Price/Book (PB) ratio is 2.65.